Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 12/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504833 | 0.92 | AVPR2 (0.54) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL381899 | 0.91 | AVPR2 (0.54) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL8233598 | 0.91 | AVPR2 (0.54) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL12057144 | 0.90 | AVPR2 (0.53) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL1442485 | 0.89 | AVPR2 (0.48) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL12057132 | 0.89 | AVPR2 (0.54) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL8227831 | 0.88 | AVPR2 (0.51) | AVPR2AVPR1ATP53MAPTGPR139 | |
| SCHEMBL8235594 | 0.88 | AVPR2 (0.52) | AVPR2AVPR1A | |
| SCHEMBL8235351 | 0.88 | AVPR2 (0.57) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL8233218 | 0.87 | AVPR2 (0.51) | AVPR2AVPR1ATP53MAPTGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885TP53 3885/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885TP53 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.